Thus, future research should establish HMGB1 as a promising target for treatment of cardiac hypertrophy in diseases such as endotoxemia, sepsis, hemorrhagic shock, rheumatoid arthritis, type 2 diabetes, hypertension, and ST-elevation myocardial infarction. Here, HMGB1 is linked to serum lipopolysaccharide activity.